Could Fenofibrate Slow Diabetic Eye Disease in Type 1 Diabetes?

Could a medication traditionally prescribed to lower triglycerides also protect the eyes of people with type 1 diabetes? New research is bringing that possibility closer to clinical discussion. The potential role of fenofibrate in slowing diabetic retinopathy among people with type 1 diabetes has gained attention following a new analysis of the randomized LENS trial, published online in Diabetes Care on October 9, 2026. Although earlier studies suggested that fenofibrate could slow diabetic eye disease, most evidence came from patients with type 2 diabetes. The latest research highlights an important question: Could this established medication offer additional protection against retinal damage in type 1 diabetes?

Table of Contents

1. Understanding Fenofibrate and Diabetic Retinopathy
2. What the LENS Trial Reveals About Type 1 Diabetes
3. How Fenofibrate May Protect the Retina
4. Clinical Implications, Safety, and Treatment Decisions
5. Conclusion
6. Frequently Asked Questions

Understanding Fenofibrate and Diabetic Retinopathy

Diabetic retinopathy develops when long-term exposure to elevated blood glucose damages small blood vessels in the retina. Over time, these vessels may leak, become blocked, or trigger abnormal blood vessel growth. Consequently, patients can experience blurred vision, retinal swelling, and potentially permanent vision loss.

People with type 1 diabetes face a substantial lifetime risk of retinal complications, particularly with longer disease duration. However, maintaining appropriate glucose levels, managing blood pressure, and attending regular retinal screenings can reduce this risk.

Fenofibrate, marketed under brand names including Tricor and Fenoglide, belongs to a medication class called fibrates. Traditionally, physicians prescribe it to manage elevated triglycerides and certain lipid disorders.

Interestingly, researchers discovered that fenofibrate might protect retinal tissue through mechanisms beyond lowering blood lipids. Earlier studies, including FIELD and ACCORD-EYE, identified reductions in diabetic retinopathy progression or the need for retinal laser treatment among people with type 2 diabetes.

These findings raised interest in using lipid-modifying medications to address diabetes-related eye complications. Nevertheless, whether similar benefits extend to patients with type 1 diabetes has remained an important unanswered clinical question.

What the LENS Trial Reveals About Type 1 Diabetes

The Lowering Events in Non-proliferative Retinopathy in Scotland (LENS) trial provides some of the strongest randomized evidence supporting fenofibrate as a possible treatment for slowing early diabetic eye disease.

Researchers enrolled 1,151 adults with diabetes and early retinal abnormalities. Approximately 26% of participants had type 1 diabetes, making this population particularly relevant to the latest analysis.

Participants received fenofibrate 145 mg or placebo, with treatment frequency adjusted for impaired kidney function. Researchers then monitored retinal outcomes over a median follow-up period of four years.

According to the original LENS findings published in NEJM Evidence, the primary retinal outcome occurred in 22.7% of fenofibrate-treated participants compared with 29.2% receiving placebo.

This represented a 27% relative reduction in the hazard of progression to referable retinopathy or maculopathy, or the need for retinal treatment. Additionally, the trial reported fewer cases of macular edema among participants receiving fenofibrate.

The original trial found no clear evidence that the proportional treatment effect differed between participants with type 1 and type 2 diabetes.

Why the New Type 1 Diabetes Analysis Matters

Published online in Diabetes Care on October 9, 2026, the new analysis by Zayed and colleagues specifically examines fenofibrate's effects on diabetic retinopathy progression in people with type 1 diabetes.

This analysis addresses a significant evidence gap because earlier fenofibrate trials primarily involved people with type 2 diabetes.

Importantly, the overall LENS results should not be confused with treatment estimates calculated specifically for the type 1 subgroup. The newly published type 1 analysis requires evaluation of its subgroup event rates, confidence intervals, and statistical precision before drawing stronger conclusions.

Furthermore, evidence that treatment effects do not significantly differ between diabetes types does not establish identical benefits for every patient.

Therefore, the findings support further research into whether fenofibrate can slow diabetic retinopathy in people with type 1 diabetes, although they do not justify recommending the drug for everyone.

How Fenofibrate May Protect the Retina

One of the most interesting aspects of fenofibrate research is that its retinal benefits may extend beyond conventional cholesterol management.

Fenofibrate activates a cellular receptor called peroxisome proliferator-activated receptor alpha, or PPAR-alpha. This receptor helps regulate fat metabolism and participates in several biological pathways associated with inflammation.

Researchers believe that activating PPAR-alpha may reduce inflammatory activity within retinal tissue. As a result, fenofibrate could potentially limit some of the cellular damage associated with diabetic retinopathy.

Additionally, laboratory research suggests that the medication may help preserve the blood-retinal barrier. This protective structure controls the movement of substances between blood vessels and delicate retinal tissue.

When the barrier becomes damaged, fluid can leak into the retina, contributing to diabetic macular edema.

Fenofibrate may also influence oxidative stress and abnormal signaling pathways involved in retinal injury. However, these proposed mechanisms remain under investigation, and laboratory findings do not prove clinical benefit on their own.

A 2025 scientific review of fenofibrate and diabetic retinopathy describes these possible effects and explains why retinal protection may occur independently of changes in circulating lipid levels.

Taken together, these findings suggest that fenofibrate could eventually serve as an additional strategy for managing early retinal disease.

Clinical Implications, Safety, and Treatment Decisions

Despite encouraging results, fenofibrate should not automatically become routine treatment for every person with type 1 diabetes.

First, the LENS trial evaluated adults who already had early retinal abnormalities. Therefore, its findings cannot establish whether fenofibrate prevents diabetic retinopathy in patients without existing retinal disease.

Second, although fenofibrate reduced retinal disease progression in the overall trial population, researchers did not demonstrate significant improvements in visual acuity or patient-reported visual function.

This distinction matters because slowing changes detected during retinal screening does not necessarily mean patients will experience better eyesight.

Safety also remains an important consideration. Fenofibrate can affect kidney function measurements and may cause adverse effects involving the liver or muscles. Furthermore, combining fibrates with certain other medications can increase the risk of muscle-related complications.

In LENS, average estimated kidney filtration measurements were lower in the fenofibrate group. However, serious adverse event rates were similar between treatment groups.

Clinicians should therefore assess kidney function, medication interactions, baseline lipid levels, and individual risk factors before considering therapy.

Meanwhile, established approaches remain essential. These include appropriate glucose management, blood pressure control, scheduled dilated retinal examinations, and timely ophthalmology referrals.

Patients with more advanced disease may also require anti-VEGF injections, retinal laser treatment, or other specialist interventions.

Ultimately, research into fenofibrate for diabetic retinopathy in type 1 diabetes should guide personalized treatment discussions rather than encourage patients to start the medication without medical advice.

Conclusion

The LENS trial has added valuable evidence that fenofibrate can reduce the progression of early diabetic retinopathy in adults with diabetes. More importantly, the newly published type 1 diabetes analysis brings attention to a population that has historically been underrepresented in fenofibrate research.

Although the overall findings are encouraging, questions remain regarding the precise benefit in type 1 diabetes, long-term visual outcomes, and patient selection.

For now, fenofibrate represents a promising potential addition to retinal disease management, not a replacement for established care. Further type 1-specific research will help clarify its clinical role.

Frequently Asked Questions

Can fenofibrate slow diabetic retinopathy in people with type 1 diabetes?

The overall LENS trial demonstrated slower progression of early diabetic retinopathy with fenofibrate, with no clear evidence that effects differed by diabetes type. However, the newly published type 1-specific analysis should be assessed independently before making definitive treatment recommendations.

Is fenofibrate FDA-approved for diabetic retinopathy?

No. In the United States, fenofibrate is not FDA-approved specifically for preventing or treating diabetic retinopathy. Its approved uses involve certain lipid disorders, although retinal indications exist in some other countries.

How does fenofibrate differ from anti-VEGF eye injections?

Fenofibrate is an oral medication being investigated for slowing retinal disease progression. Anti-VEGF injections directly target abnormal blood vessel signaling and are established treatments for certain vision-threatening retinal complications. These treatments serve different clinical purposes.

Does fenofibrate improve eyesight in patients with diabetic retinopathy?

Not necessarily. Although LENS demonstrated reduced retinal disease progression, the trial did not establish significant improvements in visual acuity or visual function. Preventing disease progression and restoring lost vision are different treatment outcomes.

Should people with type 1 diabetes ask their doctors about fenofibrate?

Patients with existing diabetic retinopathy may discuss emerging fenofibrate evidence with their diabetes care team and ophthalmologist. However, treatment decisions should consider kidney function, other medications, established indications, and the patient's overall risk profile.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.